Clinical Trial Update: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis who previously failed Dupilumab has completed and resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Lebrikizumab (lebrikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2025-03-19